News · 26 weeks65-29%
2026-04-192026-10-11
Mix4390d
- Insider31(72%)
- SEC Filings6(14%)
- Other3(7%)
- Offering1(2%)
- Analyst1(2%)
- Earnings1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Ethos Technologies Inc.4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERSEC Form 4 filed by Ethos Technologies Inc.4 - Ethos Technologies Inc. (0001788451) (Issuer)
- PREthos to Announce Third Quarter 2026 Financial Results on November 2, 2026AUSTIN, Texas, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will release its financial results for the third quarter of 2026, which ended September 30, 2026, following the close of U.S. financial markets on Monday, November 2, 2026. The company’s earnings press release will be made available on the Ethos Investor Relations website at investors.ethos.com. Ethos executives will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET the same day. The live webcast of the conference call can be found on the Ethos Investor Re
- SECSEC Form 8-K filed by Ethos Technologies Inc.8-K - Ethos Technologies Inc. (0001788451) (Filer)
- ANALYSTEthos Technologies downgraded by Analyst with a new price targetAnalyst downgraded Ethos Technologies from Overweight to Neutral and set a new price target of $37.00
- INSIDERCEO and Secretary Colis Peter George converted options into 70,000 shares and sold $2,695,425 worth of shares (70,000 units at $38.51) as part of a pre-agreed trading plan (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERPresident Wang Lingke converted options into 118,333 shares and sold $4,610,442 worth of shares (118,333 units at $38.96) as part of a pre-agreed trading plan (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- SECEthos Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Ethos Technologies Inc. (0001788451) (Filer)
- INSIDERDirector Botha Roelof acquired 72,450 shares (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERLarge owner Sc Us (Ttgp), Ltd. converted options into 2,371,501 shares and disposed of 2,371,501 shares (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERLarge owner Sc Us (Ttgp), Ltd. converted options into 1,778,626 shares and disposed of 1,778,626 shares (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERDirector Botha Roelof acquired 55,167 shares (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERCEO and Secretary Colis Peter George converted options into 55,848 shares and sold $2,795,706 worth of shares (84,448 units at $33.11) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,537,360 units (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERPresident Wang Lingke converted options into 83,197 shares and sold $3,939,733 worth of shares (118,333 units at $33.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,537,543 units (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERChief Accounting Officer Kucharski Brandt Walter sold $283,664 worth of shares (8,735 units at $32.47) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 91,648 units (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERLarge owner Sc Us (Ttgp), Ltd. converted options into 142,616 shares and sold $4,713,232 worth of shares (142,616 units at $33.05) (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERLarge owner Sc Us (Ttgp), Ltd. sold $4,713,232 worth of shares (142,616 units at $33.05) and converted options into 142,616 shares (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- SECSEC Form 144 filed by Ethos Technologies Inc.144 - Ethos Technologies Inc. (0001788451) (Subject)
- INSIDERDirector Botha Roelof acquired 51,735 shares (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERLarge owner Sc Us (Ttgp), Ltd. converted options into 1,778,626 shares and disposed of 1,778,626 shares (SEC Form 4)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- PREthos to Present at the Goldman Sachs Communacopia + Technology ConferenceAUSTIN, Texas, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief Executive Officer, will present at the Goldman Sachs Communacopia + Technology Conference. Event Details: Date: Wednesday, September 9, 2026Time: 3:45 PM PT / 6:45 PM ETWebcast: A live audio webcast of the presentation will be available on the Ethos Investor Relations website at investors.ethos.com The presentation will be archived on the company’s investor relations website for 90 days following the event. About Ethos Ethos is a leading life insurance technology company on a mis
- INSIDERPresident Wang Lingke sold $775,626 worth of shares (22,623 units at $34.28), decreasing direct ownership by 1% to 1,572,679 units (SEC Form 4) to satisfy tax liability4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERCEO and Secretary Colis Peter George sold $1,003,014 worth of shares (29,342 units at $34.18), decreasing direct ownership by 2% to 1,565,960 units (SEC Form 4) to cover withholding tax4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERChief Accounting Officer Kucharski Brandt Walter sold $2,896,791 worth of shares (83,047 units at $34.88) as part of a pre-agreed trading plan, decreasing direct ownership by 45% to 100,383 units (SEC Form 4) (tax withholding)4 - Ethos Technologies Inc. (0001788451) (Issuer)
- INSIDERChief Financial Officer Capozzi Christopher M. sold $893,875 worth of shares (26,184 units at $34.14), decreasing direct ownership by 4% to 639,044 units (SEC Form 4) to satisfy withholding tax4 - Ethos Technologies Inc. (0001788451) (Issuer)
LIFE FAQ
7 questionsWhat does Ethos Technologies Inc. do?
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized...Where does LIFE stock trade?
Ethos Technologies Inc. (LIFE) is listed on NASDAQ.What sector and industry is LIFE in?
Ethos Technologies Inc. operates in the Finance sector, Specialty Insurers industry.When did Ethos Technologies Inc. go public?
Ethos Technologies Inc. (LIFE) completed its IPO in 2026.What are analysts saying about LIFE?
Ethos Technologies Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Neutral with a $3700.00 price target on 2026-10-01. Recent price targets range from $1300.00 to $3700.00.What companies are similar to LIFE?
Notable peers in the same industry include MEIP (MEI Pharma Inc.), EPIX (ESSA Pharma Inc.), EVOK (Evoke Pharma Inc.). Compare LIFE side-by-side with any of them on Quantisnow.How can I track LIFE on Quantisnow?
Quantisnow aggregates Ethos Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LIFE to receive live email and push alerts on every new disclosure.